External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study
Different nomograms exist for the preoperative prediction of pelvic lymph-node metastatic disease in individual patients with prostate cancer (PCa). These nomograms do not incorporate modern imaging techniques such as prostate-specific membrane antigen (PSMA) positron emission tomography (PET). To d...
Gespeichert in:
| Veröffentlicht in: | European urology 2021-08, Vol.80 (2), p.234-242 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 242 |
|---|---|
| container_issue | 2 |
| container_start_page | 234 |
| container_title | European urology |
| container_volume | 80 |
| creator | Meijer, Dennie van Leeuwen, Pim J. Roberts, Matthew J. Siriwardana, Amila R. Morton, Andrew Yaxley, John W. Samaratunga, Hemamali Emmett, Louise van de Ven, Peter M. van der Poel, Henk G. Donswijk, Maarten L. Boellaard, Thierry N. Schoots, Ivo G. Oprea-Lager, Daniela E. Coughlin, Geoffrey D. Vis, André N. |
| description | Different nomograms exist for the preoperative prediction of pelvic lymph-node metastatic disease in individual patients with prostate cancer (PCa). These nomograms do not incorporate modern imaging techniques such as prostate-specific membrane antigen (PSMA) positron emission tomography (PET).
To determine the predictive performance of the Briganti 2017, Memorial Sloan Kettering Cancer Center (MSKCC), and Briganti 2019 nomograms with the addition of PSMA-PET in an international, multicenter, present-day cohort of patients undergoing robot-assisted radical prostatectomy (RARP) and extended pelvic lymph-node dissection (ePLND) for localized PCa.
All 757 eligible patients who underwent a PSMA-PET prior to RARP and ePLND in three reference centers for PCa surgery between January 2016 and November 2020 were included.
Performance of the three nomograms was assessed using the receiver operating characteristic curve–derived area under the curve (AUC), calibration plots, and decision curve analyses. Subsequently, recalibration and addition of PSMA-PET to the nomograms were performed.
Overall, 186/757 patients (25%) had pelvic lymph-node metastatic (pN1) disease on histopathological examination. AUCs of the Briganti 2017, MSKCC, and Briganti 2019 nomograms were 0.70 (95% confidence interval [95% CI]: 0.64–0.77), 0.71 (95% CI: 0.65–0.77), and 0.76 (95% CI: 0.71–0.82), respectively. PSMA-PET findings showed a significant association with pN1 disease when added to the nomograms (p |
| doi_str_mv | 10.1016/j.eururo.2021.05.006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2531539261</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0302283821003304</els_id><sourcerecordid>2531539261</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-a6138fe37b83ecf8cb036e52ff8425d24408cd64d39178c68e7162274a95df513</originalsourceid><addsrcrecordid>eNp9kV9v0zAUxSMEYmXwDRDyIy8J_hMnKQ9I1dTBpBYqsfFqufb16iqJi-1My7flo-A0Y488WbZ-9x6fc7LsPcEFwaT6dCxg8IN3BcWUFJgXGFcvsgVpapbXvMIvswVmmOa0Yc1F9iaEI8aY8SV7nV2wEtOy4nSR_Vk_RvC9bNEv2Voto3U9kr1GK63t-eIM2nkXooyQhxMoa6xCW-j2XvaAVn2099CjnQs2-oSvOxvCNHfrOnfv5ekwouhQPADapi3o2sPvAfrYjugugEbfZ6wLyDh_xnYetFXP2tA-JMHN2J0Oee90WgNRpu8ECJ_TT9FNfzYw8cnFdmijVTC9oZ9x0OPb7JWRbYB3T-dldne9vr36lm9-fL25Wm1yVeIm5rIirDHA6n3DQJlG7TGrgFNjmpJyTctEKV2Vmi1J3aiqgZpUlNalXHJtOGGX2cd578m7ZDBEkYJQ0LYpJTcEQTkjnC1pNaHljKqUa_BgxMnbTvpRECymbsVRzN2KqVuBuUjdprEPTwrDvgP9PPSvzAR8mQFIPh8seBGUhV6lOD2oKLSz_1f4C4MGvQY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2531539261</pqid></control><display><type>article</type><title>External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Meijer, Dennie ; van Leeuwen, Pim J. ; Roberts, Matthew J. ; Siriwardana, Amila R. ; Morton, Andrew ; Yaxley, John W. ; Samaratunga, Hemamali ; Emmett, Louise ; van de Ven, Peter M. ; van der Poel, Henk G. ; Donswijk, Maarten L. ; Boellaard, Thierry N. ; Schoots, Ivo G. ; Oprea-Lager, Daniela E. ; Coughlin, Geoffrey D. ; Vis, André N.</creator><creatorcontrib>Meijer, Dennie ; van Leeuwen, Pim J. ; Roberts, Matthew J. ; Siriwardana, Amila R. ; Morton, Andrew ; Yaxley, John W. ; Samaratunga, Hemamali ; Emmett, Louise ; van de Ven, Peter M. ; van der Poel, Henk G. ; Donswijk, Maarten L. ; Boellaard, Thierry N. ; Schoots, Ivo G. ; Oprea-Lager, Daniela E. ; Coughlin, Geoffrey D. ; Vis, André N.</creatorcontrib><description>Different nomograms exist for the preoperative prediction of pelvic lymph-node metastatic disease in individual patients with prostate cancer (PCa). These nomograms do not incorporate modern imaging techniques such as prostate-specific membrane antigen (PSMA) positron emission tomography (PET).
To determine the predictive performance of the Briganti 2017, Memorial Sloan Kettering Cancer Center (MSKCC), and Briganti 2019 nomograms with the addition of PSMA-PET in an international, multicenter, present-day cohort of patients undergoing robot-assisted radical prostatectomy (RARP) and extended pelvic lymph-node dissection (ePLND) for localized PCa.
All 757 eligible patients who underwent a PSMA-PET prior to RARP and ePLND in three reference centers for PCa surgery between January 2016 and November 2020 were included.
Performance of the three nomograms was assessed using the receiver operating characteristic curve–derived area under the curve (AUC), calibration plots, and decision curve analyses. Subsequently, recalibration and addition of PSMA-PET to the nomograms were performed.
Overall, 186/757 patients (25%) had pelvic lymph-node metastatic (pN1) disease on histopathological examination. AUCs of the Briganti 2017, MSKCC, and Briganti 2019 nomograms were 0.70 (95% confidence interval [95% CI]: 0.64–0.77), 0.71 (95% CI: 0.65–0.77), and 0.76 (95% CI: 0.71–0.82), respectively. PSMA-PET findings showed a significant association with pN1 disease when added to the nomograms (p < 0.001). Addition of PSMA-PET substantially improved the discriminative ability of the models yielding cross-validated AUCs of 0.76 (95% CI: 0.70–0.82), 0.77 (95% CI: 0.72–0.83), and 0.82 (95% CI: 0.76–0.87), respectively. In decision curve analyses, the addition of PSMA-PET to the three nomograms resulted in increased net benefits.
The addition of PSMA-PET to the previously developed nomograms showed substantially improved predictive performance, which suggests that PSMA-PET is a likely future candidate for a modern predictive nomogram.
Different tools have been developed to individualize the prediction of prostate cancer spread to lymph nodes before surgery. We found that the inclusion of modern imaging (prostate-specific membrane antigen positron emission tomography) improved substantially the overall performance of these prediction tools.
The addition of prostate-specific membrane antigen positron emission tomography (PSMA-PET) to the previously developed nomograms for the prediction of pelvic lymph-node metastases showed substantially improved predictive performance, which suggests that PSMA-PET is a likely future candidate for a modern predictive nomogram.</description><identifier>ISSN: 0302-2838</identifier><identifier>EISSN: 1873-7560</identifier><identifier>DOI: 10.1016/j.eururo.2021.05.006</identifier><identifier>PMID: 34024652</identifier><language>eng</language><publisher>Switzerland: Elsevier B.V</publisher><subject>Extended pelvic lymph-node dissection ; Humans ; Lymph Nodes - diagnostic imaging ; Lymph Nodes - surgery ; Lymph-node metastases ; Lymphatic Metastasis ; Male ; Nomograms ; Positron-Emission Tomography ; Prostate ; Prostate cancer ; Prostate-specific membrane antigen positron emission tomography imaging ; Prostatic Neoplasms - diagnostic imaging ; Prostatic Neoplasms - surgery ; Retrospective Studies</subject><ispartof>European urology, 2021-08, Vol.80 (2), p.234-242</ispartof><rights>2021 The Author(s)</rights><rights>Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-a6138fe37b83ecf8cb036e52ff8425d24408cd64d39178c68e7162274a95df513</citedby><cites>FETCH-LOGICAL-c408t-a6138fe37b83ecf8cb036e52ff8425d24408cd64d39178c68e7162274a95df513</cites><orcidid>0000-0002-8298-575X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.eururo.2021.05.006$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34024652$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Meijer, Dennie</creatorcontrib><creatorcontrib>van Leeuwen, Pim J.</creatorcontrib><creatorcontrib>Roberts, Matthew J.</creatorcontrib><creatorcontrib>Siriwardana, Amila R.</creatorcontrib><creatorcontrib>Morton, Andrew</creatorcontrib><creatorcontrib>Yaxley, John W.</creatorcontrib><creatorcontrib>Samaratunga, Hemamali</creatorcontrib><creatorcontrib>Emmett, Louise</creatorcontrib><creatorcontrib>van de Ven, Peter M.</creatorcontrib><creatorcontrib>van der Poel, Henk G.</creatorcontrib><creatorcontrib>Donswijk, Maarten L.</creatorcontrib><creatorcontrib>Boellaard, Thierry N.</creatorcontrib><creatorcontrib>Schoots, Ivo G.</creatorcontrib><creatorcontrib>Oprea-Lager, Daniela E.</creatorcontrib><creatorcontrib>Coughlin, Geoffrey D.</creatorcontrib><creatorcontrib>Vis, André N.</creatorcontrib><title>External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study</title><title>European urology</title><addtitle>Eur Urol</addtitle><description>Different nomograms exist for the preoperative prediction of pelvic lymph-node metastatic disease in individual patients with prostate cancer (PCa). These nomograms do not incorporate modern imaging techniques such as prostate-specific membrane antigen (PSMA) positron emission tomography (PET).
To determine the predictive performance of the Briganti 2017, Memorial Sloan Kettering Cancer Center (MSKCC), and Briganti 2019 nomograms with the addition of PSMA-PET in an international, multicenter, present-day cohort of patients undergoing robot-assisted radical prostatectomy (RARP) and extended pelvic lymph-node dissection (ePLND) for localized PCa.
All 757 eligible patients who underwent a PSMA-PET prior to RARP and ePLND in three reference centers for PCa surgery between January 2016 and November 2020 were included.
Performance of the three nomograms was assessed using the receiver operating characteristic curve–derived area under the curve (AUC), calibration plots, and decision curve analyses. Subsequently, recalibration and addition of PSMA-PET to the nomograms were performed.
Overall, 186/757 patients (25%) had pelvic lymph-node metastatic (pN1) disease on histopathological examination. AUCs of the Briganti 2017, MSKCC, and Briganti 2019 nomograms were 0.70 (95% confidence interval [95% CI]: 0.64–0.77), 0.71 (95% CI: 0.65–0.77), and 0.76 (95% CI: 0.71–0.82), respectively. PSMA-PET findings showed a significant association with pN1 disease when added to the nomograms (p < 0.001). Addition of PSMA-PET substantially improved the discriminative ability of the models yielding cross-validated AUCs of 0.76 (95% CI: 0.70–0.82), 0.77 (95% CI: 0.72–0.83), and 0.82 (95% CI: 0.76–0.87), respectively. In decision curve analyses, the addition of PSMA-PET to the three nomograms resulted in increased net benefits.
The addition of PSMA-PET to the previously developed nomograms showed substantially improved predictive performance, which suggests that PSMA-PET is a likely future candidate for a modern predictive nomogram.
Different tools have been developed to individualize the prediction of prostate cancer spread to lymph nodes before surgery. We found that the inclusion of modern imaging (prostate-specific membrane antigen positron emission tomography) improved substantially the overall performance of these prediction tools.
The addition of prostate-specific membrane antigen positron emission tomography (PSMA-PET) to the previously developed nomograms for the prediction of pelvic lymph-node metastases showed substantially improved predictive performance, which suggests that PSMA-PET is a likely future candidate for a modern predictive nomogram.</description><subject>Extended pelvic lymph-node dissection</subject><subject>Humans</subject><subject>Lymph Nodes - diagnostic imaging</subject><subject>Lymph Nodes - surgery</subject><subject>Lymph-node metastases</subject><subject>Lymphatic Metastasis</subject><subject>Male</subject><subject>Nomograms</subject><subject>Positron-Emission Tomography</subject><subject>Prostate</subject><subject>Prostate cancer</subject><subject>Prostate-specific membrane antigen positron emission tomography imaging</subject><subject>Prostatic Neoplasms - diagnostic imaging</subject><subject>Prostatic Neoplasms - surgery</subject><subject>Retrospective Studies</subject><issn>0302-2838</issn><issn>1873-7560</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kV9v0zAUxSMEYmXwDRDyIy8J_hMnKQ9I1dTBpBYqsfFqufb16iqJi-1My7flo-A0Y488WbZ-9x6fc7LsPcEFwaT6dCxg8IN3BcWUFJgXGFcvsgVpapbXvMIvswVmmOa0Yc1F9iaEI8aY8SV7nV2wEtOy4nSR_Vk_RvC9bNEv2Voto3U9kr1GK63t-eIM2nkXooyQhxMoa6xCW-j2XvaAVn2099CjnQs2-oSvOxvCNHfrOnfv5ekwouhQPADapi3o2sPvAfrYjugugEbfZ6wLyDh_xnYetFXP2tA-JMHN2J0Oee90WgNRpu8ECJ_TT9FNfzYw8cnFdmijVTC9oZ9x0OPb7JWRbYB3T-dldne9vr36lm9-fL25Wm1yVeIm5rIirDHA6n3DQJlG7TGrgFNjmpJyTctEKV2Vmi1J3aiqgZpUlNalXHJtOGGX2cd578m7ZDBEkYJQ0LYpJTcEQTkjnC1pNaHljKqUa_BgxMnbTvpRECymbsVRzN2KqVuBuUjdprEPTwrDvgP9PPSvzAR8mQFIPh8seBGUhV6lOD2oKLSz_1f4C4MGvQY</recordid><startdate>202108</startdate><enddate>202108</enddate><creator>Meijer, Dennie</creator><creator>van Leeuwen, Pim J.</creator><creator>Roberts, Matthew J.</creator><creator>Siriwardana, Amila R.</creator><creator>Morton, Andrew</creator><creator>Yaxley, John W.</creator><creator>Samaratunga, Hemamali</creator><creator>Emmett, Louise</creator><creator>van de Ven, Peter M.</creator><creator>van der Poel, Henk G.</creator><creator>Donswijk, Maarten L.</creator><creator>Boellaard, Thierry N.</creator><creator>Schoots, Ivo G.</creator><creator>Oprea-Lager, Daniela E.</creator><creator>Coughlin, Geoffrey D.</creator><creator>Vis, André N.</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8298-575X</orcidid></search><sort><creationdate>202108</creationdate><title>External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study</title><author>Meijer, Dennie ; van Leeuwen, Pim J. ; Roberts, Matthew J. ; Siriwardana, Amila R. ; Morton, Andrew ; Yaxley, John W. ; Samaratunga, Hemamali ; Emmett, Louise ; van de Ven, Peter M. ; van der Poel, Henk G. ; Donswijk, Maarten L. ; Boellaard, Thierry N. ; Schoots, Ivo G. ; Oprea-Lager, Daniela E. ; Coughlin, Geoffrey D. ; Vis, André N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-a6138fe37b83ecf8cb036e52ff8425d24408cd64d39178c68e7162274a95df513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Extended pelvic lymph-node dissection</topic><topic>Humans</topic><topic>Lymph Nodes - diagnostic imaging</topic><topic>Lymph Nodes - surgery</topic><topic>Lymph-node metastases</topic><topic>Lymphatic Metastasis</topic><topic>Male</topic><topic>Nomograms</topic><topic>Positron-Emission Tomography</topic><topic>Prostate</topic><topic>Prostate cancer</topic><topic>Prostate-specific membrane antigen positron emission tomography imaging</topic><topic>Prostatic Neoplasms - diagnostic imaging</topic><topic>Prostatic Neoplasms - surgery</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Meijer, Dennie</creatorcontrib><creatorcontrib>van Leeuwen, Pim J.</creatorcontrib><creatorcontrib>Roberts, Matthew J.</creatorcontrib><creatorcontrib>Siriwardana, Amila R.</creatorcontrib><creatorcontrib>Morton, Andrew</creatorcontrib><creatorcontrib>Yaxley, John W.</creatorcontrib><creatorcontrib>Samaratunga, Hemamali</creatorcontrib><creatorcontrib>Emmett, Louise</creatorcontrib><creatorcontrib>van de Ven, Peter M.</creatorcontrib><creatorcontrib>van der Poel, Henk G.</creatorcontrib><creatorcontrib>Donswijk, Maarten L.</creatorcontrib><creatorcontrib>Boellaard, Thierry N.</creatorcontrib><creatorcontrib>Schoots, Ivo G.</creatorcontrib><creatorcontrib>Oprea-Lager, Daniela E.</creatorcontrib><creatorcontrib>Coughlin, Geoffrey D.</creatorcontrib><creatorcontrib>Vis, André N.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Meijer, Dennie</au><au>van Leeuwen, Pim J.</au><au>Roberts, Matthew J.</au><au>Siriwardana, Amila R.</au><au>Morton, Andrew</au><au>Yaxley, John W.</au><au>Samaratunga, Hemamali</au><au>Emmett, Louise</au><au>van de Ven, Peter M.</au><au>van der Poel, Henk G.</au><au>Donswijk, Maarten L.</au><au>Boellaard, Thierry N.</au><au>Schoots, Ivo G.</au><au>Oprea-Lager, Daniela E.</au><au>Coughlin, Geoffrey D.</au><au>Vis, André N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study</atitle><jtitle>European urology</jtitle><addtitle>Eur Urol</addtitle><date>2021-08</date><risdate>2021</risdate><volume>80</volume><issue>2</issue><spage>234</spage><epage>242</epage><pages>234-242</pages><issn>0302-2838</issn><eissn>1873-7560</eissn><abstract>Different nomograms exist for the preoperative prediction of pelvic lymph-node metastatic disease in individual patients with prostate cancer (PCa). These nomograms do not incorporate modern imaging techniques such as prostate-specific membrane antigen (PSMA) positron emission tomography (PET).
To determine the predictive performance of the Briganti 2017, Memorial Sloan Kettering Cancer Center (MSKCC), and Briganti 2019 nomograms with the addition of PSMA-PET in an international, multicenter, present-day cohort of patients undergoing robot-assisted radical prostatectomy (RARP) and extended pelvic lymph-node dissection (ePLND) for localized PCa.
All 757 eligible patients who underwent a PSMA-PET prior to RARP and ePLND in three reference centers for PCa surgery between January 2016 and November 2020 were included.
Performance of the three nomograms was assessed using the receiver operating characteristic curve–derived area under the curve (AUC), calibration plots, and decision curve analyses. Subsequently, recalibration and addition of PSMA-PET to the nomograms were performed.
Overall, 186/757 patients (25%) had pelvic lymph-node metastatic (pN1) disease on histopathological examination. AUCs of the Briganti 2017, MSKCC, and Briganti 2019 nomograms were 0.70 (95% confidence interval [95% CI]: 0.64–0.77), 0.71 (95% CI: 0.65–0.77), and 0.76 (95% CI: 0.71–0.82), respectively. PSMA-PET findings showed a significant association with pN1 disease when added to the nomograms (p < 0.001). Addition of PSMA-PET substantially improved the discriminative ability of the models yielding cross-validated AUCs of 0.76 (95% CI: 0.70–0.82), 0.77 (95% CI: 0.72–0.83), and 0.82 (95% CI: 0.76–0.87), respectively. In decision curve analyses, the addition of PSMA-PET to the three nomograms resulted in increased net benefits.
The addition of PSMA-PET to the previously developed nomograms showed substantially improved predictive performance, which suggests that PSMA-PET is a likely future candidate for a modern predictive nomogram.
Different tools have been developed to individualize the prediction of prostate cancer spread to lymph nodes before surgery. We found that the inclusion of modern imaging (prostate-specific membrane antigen positron emission tomography) improved substantially the overall performance of these prediction tools.
The addition of prostate-specific membrane antigen positron emission tomography (PSMA-PET) to the previously developed nomograms for the prediction of pelvic lymph-node metastases showed substantially improved predictive performance, which suggests that PSMA-PET is a likely future candidate for a modern predictive nomogram.</abstract><cop>Switzerland</cop><pub>Elsevier B.V</pub><pmid>34024652</pmid><doi>10.1016/j.eururo.2021.05.006</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-8298-575X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0302-2838 |
| ispartof | European urology, 2021-08, Vol.80 (2), p.234-242 |
| issn | 0302-2838 1873-7560 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2531539261 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Extended pelvic lymph-node dissection Humans Lymph Nodes - diagnostic imaging Lymph Nodes - surgery Lymph-node metastases Lymphatic Metastasis Male Nomograms Positron-Emission Tomography Prostate Prostate cancer Prostate-specific membrane antigen positron emission tomography imaging Prostatic Neoplasms - diagnostic imaging Prostatic Neoplasms - surgery Retrospective Studies |
| title | External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T23%3A36%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=External%20Validation%20and%20Addition%20of%20Prostate-specific%20Membrane%20Antigen%20Positron%20Emission%20Tomography%20to%20the%20Most%20Frequently%20Used%20Nomograms%20for%20the%20Prediction%20of%20Pelvic%20Lymph-node%20Metastases:%20an%20International%20Multicenter%20Study&rft.jtitle=European%20urology&rft.au=Meijer,%20Dennie&rft.date=2021-08&rft.volume=80&rft.issue=2&rft.spage=234&rft.epage=242&rft.pages=234-242&rft.issn=0302-2838&rft.eissn=1873-7560&rft_id=info:doi/10.1016/j.eururo.2021.05.006&rft_dat=%3Cproquest_cross%3E2531539261%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2531539261&rft_id=info:pmid/34024652&rft_els_id=S0302283821003304&rfr_iscdi=true |